The Business Research Company’s report on the Viral And Non-Viral Vector Manufacturing Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
#How have key drivers contributed to the rapid growth of the viral and non-viral vector manufacturing market?
The increasing prevalence of genetic disorders is expected to propel the growth of the viral and non-viral vector manufacturing markets going forward. Genetic disorders refer to a condition entirely or partially brought on by a deviation from the typical DNA sequence. Viral vectors deliver therapeutic genes to target cells, replacing or supplementing the defective genes that cause genetic disorders. Non-viral vectors are often used in ex vivo gene therapy approaches, where cells are genetically modified outside the body and then reinfused into the patient. For instance, in June 2022, according to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes had increased to 10.5% worldwide, with over half (44.7%) of people still undiagnosed and around 783 million adults, or one in eight people, expected to have diabetes by 2045. Therefore, the increasing incidence of genetic disorders drives the growth of the viral and non-viral vector manufacturing market.
Access Your Free Sample of the Global Viral And Non-Viral Vector Manufacturing Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp
How has the viral and non-viral vector manufacturing market size evolved, and what are the latest forecasts for its expansion?
The viral and non-viral vector manufacturing market size has grown rapidly in recent years. It will grow from $8.67 billion in 2024 to $10.3 billion in 2025 at a compound annual growth rate (CAGR) of 18.8%. The growth in the historic period can be attributed to the rising prevalence of genetic disorders, advancements in biotechnology, increasing investments in gene therapy research, growing awareness of personalized medicine, and regulatory support for gene therapy development
The viral and non-viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $22.06 billion in 2029 at a compound annual growth rate (CAGR) of 21.0%. The growth in the forecast period can be attributed to rising demand for gene therapies, expanding applications in rare disease treatment, increasing investments in biomanufacturing infrastructure, and growing adoption of precision medicine. Major trends in the forecast period include the development of next-generation viral vectors, increased use of CRISPR or cas9 technology in vector manufacturing, focus on scalable and cost-effective manufacturing processes, rising adoption of non-viral vectors, and advancements in cell and gene therapy manufacturing technologies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12570&type=smp
Which major companies dominate the viral and non-viral vector manufacturing market?
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
What trends will shape the future of the video telemedicine market?
Technological advancements are a key trend gaining popularity in the viral and non-viral vector manufacturing markets. Major companies operating in the viral and non-viral vector manufacturing markets are developing technologically advanced solutions to sustain their position in the market. For instance, in August 2022, Merck KGaA, a Germany-based science and technology company, launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. One of the first Contract development and manufacturing organizations and technology creators to offer an entire viral vector manufacturing package, including AAV, Lentiviral, CDMO, CTO, and process development. With the help of this innovative platform, biopharmaceutical businesses may shorten the time and expense of process development while accelerating the time to clinical manufacture.
Which region dominates the viral and non-viral vector manufacturing market, and what factors contribute to its leadership?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
How is the viral and non-viral vector manufacturing market segmented, and which segment holds the largest share?
The viral and non-viral vector manufacturing market covered in this report is segmented –
1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications
Subsegments:
1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12570
How is the viral and non-viral vector manufacturing market defined?
Viral and non-viral vector manufacturing refers to producing viral and non-viral vectors, tools that deliver genetic material into cells. Viral vectors treat human diseases and are used in anticancer and gene therapies. Non-viral vectors are utilized for a variety of gene therapy applications, particularly for the creation of vaccines and the treatment of cancer.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
